The use of economic analysis in formulary decision making in the United States hasn’t had a real strong past, however, in the past 2 years, the Institute for Clinical and Economic Review (ICER) has produced value assessments, representing a shift in the availability of independent evidence. How will these reports impact reimbursement and value assessment trends in the United States, and what impact will they have in Europe? Dymaxium recently conducted two surveys of US payers’ use of ICER reports, you can find out more here. (Source: Allen Lising, Value & Outcomes Spotlight, March/April 2017)
You are here: / / What Impact Will ICER Reports Have in Europe?